Prazosin dosed 3 times a day to treat flashbacks related to PTSD: A case report.

The Mental Health Clinician Pub Date : 2022-08-23 eCollection Date: 2022-08-01 DOI:10.9740/mhc.2022.08.267
Christie Richardson, Alexander Swartz, Martin Forsberg
{"title":"Prazosin dosed 3 times a day to treat flashbacks related to PTSD: A case report.","authors":"Christie Richardson,&nbsp;Alexander Swartz,&nbsp;Martin Forsberg","doi":"10.9740/mhc.2022.08.267","DOIUrl":null,"url":null,"abstract":"<p><p>Prazosin is an alpha-1 adrenergic receptor antagonist widely known by mental health providers for its off-label use for nightmares in patients with PTSD. Prazosin is lipophilic and crosses the blood-brain barrier to antagonize alpha-1 receptors in the central nervous system, potentially reducing autonomic arousal caused by PTSD. There have been numerous case reports describing the reduction of nightmares and daytime flashbacks due to PTSD with prazosin dosed at night and during the day, respectively. This case report illustrates the resolution of flashbacks related to chronic PTSD with prazosin dosed 3 times a day. As the half-life of prazosin is only 2 to 3 hours, even a twice daily dosing regimen may lead to breakthrough symptoms between doses. This case proposes a unique dosing strategy for prazosin and need for further research utilizing multiple daily doses of prazosin in the treatment of PTSD.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 4","pages":"267-269"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/52/i2168-9709-12-4-267.PMC9405631.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2022.08.267","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Prazosin is an alpha-1 adrenergic receptor antagonist widely known by mental health providers for its off-label use for nightmares in patients with PTSD. Prazosin is lipophilic and crosses the blood-brain barrier to antagonize alpha-1 receptors in the central nervous system, potentially reducing autonomic arousal caused by PTSD. There have been numerous case reports describing the reduction of nightmares and daytime flashbacks due to PTSD with prazosin dosed at night and during the day, respectively. This case report illustrates the resolution of flashbacks related to chronic PTSD with prazosin dosed 3 times a day. As the half-life of prazosin is only 2 to 3 hours, even a twice daily dosing regimen may lead to breakthrough symptoms between doses. This case proposes a unique dosing strategy for prazosin and need for further research utilizing multiple daily doses of prazosin in the treatment of PTSD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
每天服用三次哌唑嗪治疗与PTSD相关的闪回:一例报告。
普拉唑嗪是一种α -1肾上腺素受体拮抗剂,因其在标签外用于治疗PTSD患者的噩梦而被精神健康提供者广泛知晓。哌唑嗪具有亲脂性,可穿过血脑屏障对抗中枢神经系统中的α -1受体,潜在地减少PTSD引起的自主神经觉醒。有许多案例报告描述了分别在夜间和白天服用哌唑嗪可以减少创伤后应激障碍患者的噩梦和白天闪回。本病例报告说明解决与慢性创伤后应激障碍的闪回与吡唑嗪每天服用3次。由于哌唑嗪的半衰期仅为2 ~ 3小时,即使每天两次给药也可能导致两次给药之间出现突破性症状。本病例提出了一种独特的哌唑嗪给药策略,并需要进一步研究利用多剂量的哌唑嗪治疗PTSD。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital Barriers to access to psychiatric medications in Missouri county jails Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1